keyword
MENU ▼
Read by QxMD icon Read
search

Pulmonary vaccine delivery

keyword
https://www.readbyqxmd.com/read/29230061/boosting-with-recombinant-mva-expressing-m-tuberculosis-%C3%AE-crystallin-antigen-augments-the-protection-imparted-by-bcg-against-tuberculosis-in-guinea-pigs
#1
Prachi Nangpal, Ritika Kar Bahal, Anil K Tyagi
Tuberculosis (TB) is one of the major causes of mortality all over the globe. BCG, the only vaccine available against this disease has been successful in preventing the severe forms of childhood TB. However, the unsatisfactory performance of BCG in controlling the adult pulmonary tuberculosis has made the development of an effective vaccine against M. tuberculosis a prime objective of the TB research. In this study, a genetically stable, marker-free recombinant MVA expressing α-crystallin of M. tuberculosis (rMVA...
December 11, 2017: Scientific Reports
https://www.readbyqxmd.com/read/29219058/macrophage-targeted-cellular-carriers-for-effective-delivery-of-anti-tubercular-drugs
#2
S Beg, Jaya Agnihotri, Shibhna Singh, Mohammad Wais
Newly developed vaccine VPM1002 confers paradigm swing in the prophylactic treatment of tuberculosis (TB).Multi drug resistant and latent TB in adults as well as in underprivileged patients is instigating menace over world population if the host is immune-compromised. One third of the world's population is infected with TB. Recently it is estimated around 9.6 million people around the world became sick with TB disease. There were 1.5 million TB-related deaths worldwide. Therefore with the advent in biotechnology and Nano engineering, newly adapted survival molecular mechanism of Mycobacterium tuberculosis, new targets receptors on alveolar macrophages must be explored out for eradication of TB from the globe...
December 7, 2017: Recent Patents on Anti-infective Drug Discovery
https://www.readbyqxmd.com/read/29210987/prophylactic-sublingual-immunization-with-mycobacterium-tuberculosis-subunit-vaccine-incorporating-the-natural-killer-t-cell-agonist-alpha-galactosylceramide-enhances-protective-immunity-to-limit-pulmonary-and-extra-pulmonary-bacterial-burden-in-mice
#3
Arshad Khan, Shailbala Singh, Gloria Galvan, Chinnaswamy Jagannath, K Jagannadha Sastry
Infection by Mycobacterium tuberculosis (Mtb) remains a major global concern and the available Bacillus Calmette-Guerin (BCG) vaccine is poorly efficacious in adults. Therefore, alternative vaccines and delivery strategies focusing on Mtb antigens and appropriate immune stimulating adjuvants are needed to induce protective immunity targeted to the lungs, the primary sites of infections and pathology. We present here evidence in support of mucosal vaccination by the sublingual route in mice using the subunit Mtb antigens Ag85B and ESAT-6 adjuvanted with the glycolipid alpha-galactosylceramide (α-GalCer), a potent natural killer T (NKT) cell agonist...
December 6, 2017: Vaccines
https://www.readbyqxmd.com/read/29184017/vaccination-with-recombinant-cryptococcus-proteins-in-glucan-particles-protects-mice-against-cryptococcosis-in-a-manner-dependent-upon-mouse-strain-and-cryptococcal-species
#4
Charles A Specht, Chrono K Lee, Haibin Huang, Maureen M Hester, Jianhua Liu, Bridget A Luckie, Melanie A Torres Santana, Zeynep Mirza, Payam Khoshkenar, Ambily Abraham, Zu T Shen, Jennifer K Lodge, Ali Akalin, Jane Homan, Gary R Ostroff, Stuart M Levitz
Development of a vaccine to protect against cryptococcosis is a priority given the enormous global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery system, we previously demonstrated that mice vaccinated with crude Cryptococcus-derived alkaline extracts were protected against lethal challenge with Cryptococcus neoformans and Cryptococcus gattii The goal of the present study was to identify protective protein antigens that could be used in a subunit vaccine. Using biased and unbiased approaches, six candidate antigens (Cda1, Cda2, Cda3, Fpd1, MP88, and Sod1) were selected, recombinantly expressed in Escherichia coli, purified, and loaded into GPs...
November 28, 2017: MBio
https://www.readbyqxmd.com/read/29174315/workshop-report-nucleic-acid-delivery-devices-for-hiv-vaccines-workshop-proceedings-national-institute-of-allergy-and-infectious-diseases-bethesda-maryland-usa-may-21-2015
#5
Bruce G Weniger, Ian E Anglin, Tina Tong, Michael Pensiero, Jeffrey K Pullen
On May 21st, 2015, the U.S. National Institute of Allergy and Infectious Diseases (NIAID) convened a workshop on delivery devices for nucleic acid (NA) as vaccines in order to review the landscape of past and future technologies for administering NA (e.g., DNA, RNA, etc.) as antigen into target tissues of animal models and humans. Its focus was on current and future applications for preventing and treating human immunodeficiency virus (HIV) infection and acquired immune deficiency syndrome (AIDS) disease, among other infectious-disease priorities...
November 21, 2017: Vaccine
https://www.readbyqxmd.com/read/29141136/systemic-mrna-delivery-to-the-lungs-by-functional-polyester-based-carriers
#6
Yunfeng Yan, Hu Xiong, Xinyi Zhang, Qiang Cheng, Daniel John Siegwart
Messenger RNA (mRNA) has recently come into focus as an emerging therapeutic class with great potential for protein replacement therapy, cancer immunotherapy, regenerative medicine, vaccines, and gene editing. However, the lack of effective and safe delivery methods impedes the broad application of mRNA-based therapeutics. Here, we report a robust approach to develop efficient polymeric delivery carriers for mRNA. Lead polyesters were identified by in vitro screening of a 480-member combinatorially modified poly(trimethylolpropane allyl ether-co-suberoyl chloride) library for the delivery of luciferase encoding mRNA (Luc mRNA) to IGROV1 cells...
November 15, 2017: Biomacromolecules
https://www.readbyqxmd.com/read/29046894/fatty-acid-mimetic-micelles-for-dual-delivery-of-antigens-and-imidazoquinoline-adjuvants
#7
Sema Sevimli, Frances C Knight, Pavlo Gilchuk, Sebastian Joyce, John T Wilson
Vaccine design has undergone a shift towards the use of purified protein subunit vaccines, which offer increased safety and greater control over antigen specificity, but at the expense of immunogenicity. Here we report the development of a new polymer-based vaccine delivery platform engineered to enhance immunity through the co-delivery of protein antigens and the Toll-like receptor 7 (TLR7) agonist imiquimod (IMQ). Owing to the preferential solubility of IMQ in fatty acids, a series of block copolymer micelles with a fatty acid-mimetic core comprising lauryl methacrylate (LMA) and methacrylic acid (MAA), and a poly(ethylene glycol) methyl ether methacrylate (PEGMA) corona decorated with pyridyl disulfide ethyl methacrylate (PDSM) moieties for antigen conjugation were synthesized via reversible addition-fragmentation chain transfer (RAFT) polymerization...
February 13, 2017: ACS Biomaterials Science & Engineering
https://www.readbyqxmd.com/read/28994770/intratracheal-inoculation-of-fischer-344-rats-with-francisella-tularensis
#8
Jesse Q Nguyen, Xhavit Zogaj, Aanuoluwa A Adelani, Ping Chu, Jieh-Juen Yu, Bernard P Arulanandam, Karl E Klose
Pulmonary infection with the bacterium Francisella tularensis can lead to the serious and potentially fatal disease, tularemia, in humans. Due to the current lack of an approved tularemia vaccine for humans, research is focused on vaccine development utilizing appropriate animal models. The Fischer 344 rat has emerged as a model that reflects human susceptibility to F. tularensis infection, and thus is an attractive model for tularemia vaccine development. Intratracheal inoculation of the Fischer 344 rat with F...
September 30, 2017: Journal of Visualized Experiments: JoVE
https://www.readbyqxmd.com/read/28936747/exosomes-outlook-for-future-cell-free-cardiovascular-disease-therapy
#9
Bahar Barani, Sheeja Rajasingh, Johnson Rajasingh
Cardiovascular diseases are the number one cause of death globally with an estimated 7.4 million people dying from coronary heart disease. Studies have been conducted to identify the therapeutic utility of exosomes in many diseases, including cardiovascular diseases. It has been demonstrated that exosomes are immune modulators, can be used to treat cardiac ischemic injury, pulmonary hypertension and many other diseases, including cancers. Exosomes can be used as a biomarker for disease and cell-free drug delivery system for targeting the cells...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28827285/cxcr3-signaling-is-required-for-restricted-homing-of-parenteral-tuberculosis-vaccine-induced-t-cells-to-both-the-lung-parenchyma-and-airway
#10
Mangalakumari Jeyanathan, Sam Afkhami, Amandeep Khera, Talveer Mandur, Daniela Damjanovic, Yushi Yao, Rocky Lai, Siamak Haddadi, Anna Dvorkin-Gheva, Manel Jordana, Steven L Kunkel, Zhou Xing
Although most novel tuberculosis (TB) vaccines are designed for delivery via the muscle or skin for enhanced protection in the lung, it has remained poorly understood whether systemic vaccine-induced memory T cells can readily home to the lung mucosa prior to and shortly after pathogen exposure. We have investigated this issue by using a model of parenteral TB immunization and intravascular immunostaining. We find that systemically induced memory T cells are restricted to the blood vessels in the lung, unable to populate either the lung parenchymal tissue or the airway under homeostatic conditions...
October 1, 2017: Journal of Immunology: Official Journal of the American Association of Immunologists
https://www.readbyqxmd.com/read/28818565/raw-starch-microparticles-have-immunostimulant-activity-in-mice-vaccinated-with-bcg-and-challenged-with-mycobacterium-tuberculosis
#11
Silvia Moreno-Mendieta, Jorge Barrios-Payán, Dulce Mata-Espinosa, Sergio Sánchez, Rogelio Hernández-Pando, Romina Rodríguez-Sanoja
The main challenge for vaccine development or improvement is the lack of safe adjuvants or immunostimulants that induce protective immune responses and can be used for mucosal immunization, which is a highly desirable strategy for vaccination against infectious diseases acquired by oral or intranasal routes. One promising alternative is the use of biodegradable and biocompatible polymeric microparticles. Recently, we developed an immobilization and delivery system with starch microparticles (SMPs) and a starch-binding domain (SBDtag) suitable for the mucosal administration of antigens and the induction of antigen-specific immune responses...
August 14, 2017: Vaccine
https://www.readbyqxmd.com/read/28686604/boosting-efferocytosis-in-alveolar-space-using-bcg-vaccine-to-protect-host-against-influenza-pneumonia
#12
Sanjay Mukherjee, Renuka Subramaniam, Han Chen, Anthony Smith, Shiva Keshava, Homayoun Shams
Efferocytosis by alveolar phagocytes (APs) is pivotal in maintenance of lung homeostasis. Increased efferocytosis by APs results in protection against lethal acute lung injury due to pulmonary infections whereas defective efferocytosis by APs results in chronic lung inflammation. In this report, we show that pulmonary delivery of Bacillus Calmette-Guerin (BCG) significantly enhances efferocytosis by APs. Increased efferocytosis by APs maintains lung homeostasis and protects mice against lethal influenza pneumonia...
2017: PloS One
https://www.readbyqxmd.com/read/28639138/veterinary-vaccine-nanotechnology-pulmonary-and-nasal-delivery-in-livestock-animals
#13
REVIEW
Daniella Calderon-Nieva, Kalhari Bandara Goonewardene, Susantha Gomis, Marianna Foldvari
Veterinary vaccine development has several similarities with human vaccine development to improve the overall health and well-being of species. However, veterinary goals lean more toward feasible large-scale administration methods and low cost to high benefit immunization. Since the respiratory mucosa is easily accessible and most infectious agents begin their infection cycle at the mucosa, immunization through the respiratory route has been a highly attractive vaccine delivery strategy against infectious diseases...
August 2017: Drug Delivery and Translational Research
https://www.readbyqxmd.com/read/28463465/dendritic-cell-targeting-dna-based-nasal-adjuvants-for-protective-mucosal-immunity-to-streptococcus-pneumoniae
#14
REVIEW
Kosuke Kataoka, Yoshiko Fukuyama, David E Briles, Tatsuro Miyake, Kohtaro Fujihashi
To develop safe vaccines for inducing mucosal immunity to major pulmonary bacterial infections, appropriate vaccine antigens (Ags), delivery systems and nontoxic molecular adjuvants must be considered. Such vaccine constructs can induce Ag-specific immune responses that protect against mucosal infections. In particular, it has been shown that simply mixing the adjuvant with the bacterial Ag is a relatively easy means of constructing adjuvant-based mucosal vaccine preparations; the resulting vaccines can elicit protective immunity...
June 2017: Microbiology and Immunology
https://www.readbyqxmd.com/read/28413132/development-of-an-intradermal-dna-vaccine-delivery-strategy-to-achieve-single-dose-immunity-against-respiratory-syncytial-virus
#15
Trevor R F Smith, Katherine Schultheis, Matthew P Morrow, Kimberly A Kraynyak, Jay R McCoy, Kevin C Yim, Karuppiah Muthumani, Laurent Humeau, David B Weiner, Niranjan Y Sardesai, Kate E Broderick
Respiratory syncytial virus (RSV) is a massive medical burden in infants, children and the elderly worldwide, and an effective, safe RSV vaccine remains an unmet need. Here we assess a novel vaccination strategy based on the intradermal delivery of a SynCon® DNA-based vaccine encoding engineered RSV-F antigen using a surface electroporation device (SEP) to target epidermal cells, in clinically relevant experimental models. We demonstrate the ability of this strategy to elicit robust immune responses. Importantly we demonstrate complete resistance to pulmonary infection at a single low dose of vaccine in the cotton rat RSV/A challenge model...
May 15, 2017: Vaccine
https://www.readbyqxmd.com/read/28210505/nanotechnology-based-approach-in-tuberculosis-treatment
#16
REVIEW
Mohammad Nasiruddin, Md Kausar Neyaz, Shilpi Das
Tuberculosis, commonly known as TB, is the second most fatal infectious disease after AIDS, caused by bacterium called Mycobacterium tuberculosis. Prolonged treatment, high pill burden, low compliance, and stiff administration schedules are factors that are responsible for emergence of MDR and XDR cases of tuberculosis. Till date, only BCG vaccine is available which is ineffective against adult pulmonary TB, which is the most common form of disease. Various unique antibodies have been developed to overcome drug resistance, reduce the treatment regimen, and elevate the compliance to treatment...
2017: Tuberculosis Research and Treatment
https://www.readbyqxmd.com/read/28004802/targeting-dendritic-cells-to-accelerate-t-cell-activation-overcomes-a-bottleneck-in-tuberculosis-vaccine-efficacy
#17
Kristin L Griffiths, Mushtaq Ahmed, Shibali Das, Radha Gopal, William Horne, Terry D Connell, Kelly D Moynihan, Jay K Kolls, Darrell J Irvine, Maxim N Artyomov, Javier Rangel-Moreno, Shabaana A Khader
The development of a tuberculosis (TB) vaccine that induces sterilizing immunity to Mycobacterium tuberculosis infection has been elusive. Absence of sterilizing immunity induced by TB vaccines may be due to delayed activation of mucosal dendritic cells (DCs), and subsequent delay in antigen presentation and activation of vaccine-induced CD4(+) T-cell responses. Here we show that pulmonary delivery of activated M. tuberculosis antigen-primed DCs into vaccinated mice, at the time of M. tuberculosis exposure, can overcome the delay in accumulation of vaccine-induced CD4(+) T-cell responses...
December 22, 2016: Nature Communications
https://www.readbyqxmd.com/read/27910739/overview-on-therapeutic-applications-of-microparticulate-drug-delivery-systems
#18
REVIEW
Swarna Bale, Amit Khurana, A Shiva Shankar Reddy, Mandip Singh, Chandraiah Godugu
Research in novel drug delivery systems is being explored competitively in order to attain maximum therapeutic effect while minimizing the adverse effects. Despite several advancements in pharmaceutical formulations, one of the major challenges still persisting is sustained drug release. Microencapsulation enacts as an intelligent approach with a strong therapeutic impact and is in demand globally in medical technology due to its specific and attractive properties, including biocompatibility, stability, target specificity, uniform encapsulation, better compliance, and controlled and sustained release patterns that are responsible for diminishing the toxicity and dosage frequency...
2016: Critical Reviews in Therapeutic Drug Carrier Systems
https://www.readbyqxmd.com/read/27823900/gene-based-neonatal-immune-priming-potentiates-a-mucosal-adenoviral-vaccine-encoding-mycobacterial-ag85b
#19
Guixiang Dai, Hamada F Rady, Weitao Huang, Judd E Shellito, Carol Mason, Alistair J Ramsay
Tuberculosis remains a major public health hazard worldwide, with neonates and young infants potentially more susceptible to infection than adults. BCG, the only vaccine currently available, provides some protection against tuberculous meningitis in children but variable efficacy in adults, and is not safe to use in immune compromised individuals. A safe and effective vaccine that could be given early in life, and that could also potentiate subsequent booster immunization, would represent a significant advance...
December 7, 2016: Vaccine
https://www.readbyqxmd.com/read/27610066/nicotine-replacement-therapy-an-overview
#20
REVIEW
Umesh Wadgave, L Nagesh
Today tobacco use is the single greatest preventable cause of death in the world. Tobacco use is often incorrectly perceived to be solely a personal choice. This is contradicted by the fact that when fully aware of the health impact, most tobacco users want to quit but find it difficult to stop due to the addictiveness of nicotine. Henceforth, Nicotine replacement therapy (NRT) came into existence which temporarily replaces much of the nicotine from tobacco to reduce motivation to consume tobacco and nicotine withdrawal symptoms, thus easing the transition from cigarette smoking to complete abstinence...
July 2016: International Journal of Health Sciences
keyword
keyword
52494
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"